How the Target Determines the Clinical Effect
The correlation between the drug's site of action and its ultimate clinical effect is a fundamental concept in pharmacology. The type of impact on the microflora strictly depends on which specific bacterial structure the drug attacks.
There are two main types of antimicrobial action:
- Bactericidal effect. The drug causes irreversible damage and complete cell death. This occurs when critical survival structures are targeted: the cell wall, the cytoplasmic membrane (via altered permeability), or RNA synthesis pathways.
- Bacteriostatic effect. The growth and replication of the pathogen are halted, but the cell remains viable. This effect is typical of agents that disrupt intracellular protein synthesis at the ribosomal level.
Understanding this correlation allows clinicians to accurately predict the therapeutic outcome of antimicrobial therapy.
Disruption of Cell Wall and Membrane Synthesis
A significant proportion of antimicrobials target the outer envelopes of the microorganism. Blocking the formation of these structures invariably leads to a bactericidal effect.
1. Inhibition of Cell Wall Synthesis These drugs target the outer shell of the bacterium, preventing the formation of a rigid peptidoglycan meshwork or disrupting its integrity. Consequently, the cell loses structural defense and lyses. This group includes:
- Beta-lactam antibiotics (the primary and most extensive class);
- Glycopeptide antibiotics;
- Various agents from other classes: cycloserine, bacitracin, fosfomycin.
2. Destabilization of the Cytoplasmic Membrane This group of drugs destabilizes the membrane, critically altering its permeability. Vital intracellular components leak out, leading to cell death. Membrane-active agents include:
- Polymyxins;
- Polyene antimycotics (agents with prominent antifungal activity);
- Aminoglycosides (a unique group with a dual mechanism: alongside inhibiting protein synthesis, they disrupt membrane permeability).
Blockade of Metabolism and Protein Synthesis
For active replication, bacteria must continuously synthesize new protein molecules and nucleotides. Interference with intracellular processes deprives them of this capability.
Metabolic Disruption (Folic Acid Synthesis) These drugs block sequential steps in the conversion of para-aminobenzoic acid (PABA) into active folates, which are absolutely essential for nucleotide synthesis. The pathway is inhibited at two stages:
- First stage: Conversion of PABA to dihydrofolic acid (DFA). This step is targeted by sulfonamides, which act as competitive inhibitors of dihydropteroate synthase.
- Second stage: Conversion of DFA to tetrahydrofolic acid (TFA) via the enzyme dihydrofolate reductase. This step is blocked by trimethoprim.
Inhibition of Protein Synthesis at the Ribosomal Level These drugs bind to specific subunits of the bacterial ribosome, physically blocking mRNA translation. The mechanism of action is overwhelmingly bacteriostatic. Typical protein synthesis inhibitors include macrolides, tetracyclines, lincosamides, and chloramphenicol. An exception to this rule is aminoglycosides, which—despite targeting ribosomes—exert a potent bactericidal effect.
Interference with the Genetic Apparatus
A distinct category of drugs acts directly on the genetic apparatus of the bacterial cell, blocking DNA replication and transcription (nucleic acid synthesis).
Interference with this complex machinery leads to rapid cell death; thus, these agents exhibit a bactericidal type of action. A classic example of RNA synthesis inhibition is rifampin.